Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
Precision BioSciences, Inc. (Nasdaq: DTIL) will report its Q3 2020 financial results and provide a business update on November 10, 2020. The company focuses on its proprietary ARCUS genome editing platform, aiming to treat genetic and infectious diseases through CAR T immunotherapy and in vivo gene correction therapies. Precision BioSciences is dedicated to enhancing therapeutic safety and efficacy, and aims to develop 'off-the-shelf' solutions where current treatments are inadequate.
- None.
- None.
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Investor Contact:
Alex Kelly
Chief Corporate Affairs Officer
Alex.Kelly@precisionbiosciences.com
FAQ
When will Precision BioSciences release its Q3 2020 financial results?
What is the focus of Precision BioSciences?
What is the stock symbol for Precision BioSciences?
